Travel to UK must be boycotted and curbs be criticized prokerala.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prokerala.com Daily Mail and Mail on Sunday newspapers.
World Health Organization s Approval For Covaxin Likely This Month: Report ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
Mix of Covishield, Covaxin vaccine doses give better immunity against COVID-19, says ICMR study - A mix of Covishield and Covaxin vaccines doses can yield better results, an ICMR study has revealed.
To Boost International Recognition, Govt Planning To Hold Covaxin s Clinical Trials In Bangladesh swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.
Phase 3 trial: Covaxin 77.8% effective against symptomatic COVID-19, 65.2% against Delta Variant
The vaccine demonstrated 93.4% efficacy against severe symptomatic cases company said. The results are based on the evaluation of 130 confirmed cases. (Image Source: Reuters)
Updated: Jul 3, 2021, 11:11 AM IST
Hyderabad-based Bharat biotech s Covaxin has been found to be 77.8% effective against symptomatic COVID-19 in its phase 3 clinical trials. It also showed 65.2% efficacy against the Delta Plus variant. The results are based on the evaluation of 130 confirmed cases.
The indigenously developed vaccine demonstrated 93.4% efficacy against severe symptomatic COVID-19, the company claimed.
The safety analysis demonstrated that adverse events reported post-vaccination were similar for Covaxin and the placebo. Twelve percent of subjects experienced commonly known side effects and less than 0.5% of subjects felt serious adverse events.